Abstract
Prostate cancer (PCa) is one of the leading diseases in men all over the world caused due to over-expression of PSMA (Prostate Specific Membrane Antigen). Currently, the detection and targeting of PCa is one of the major challenges in prostate gland. Therefore, Bruton Tyrosine Kinase Inhibitor molecules like Ibrutinib (Ibr) loaded with nanomaterials like Multi walled Carbon nanotubes (MWCNTs), which has good physico-chemical properties may be a best regimen to treat PCa. In this strategy, the chemically modified MWCNTs which have excellent ‘Biosensing’ properties therefore makes easy for detecting PCa without fluorescent agent and thus targets particular site of PCa. In the present study, Ibr/MWCNTs conjugated with T30 oligonucleotide may target and inhibit PSMA thereby reduce the over-expression in PCa. Hence, the proposed formulation design can extensively reduce the dosage regimen without any toxic effect. Additionally, the present hypothesis also revealed the binding mode of Ibr in catalytic pocket of PSMA by in silico method. Therefore, we presume that if this hypothesis proves correct, it becomes an additional novel tool and one of the conceivable therapeutic options in treating PCa.
Publisher
Maad Rayan Publishing Company
Subject
General Pharmacology, Toxicology and Pharmaceutics,Pharmaceutical Science